弗卢瓦斯塔丁用于预防第一次皮肤冠状动脉干预成功后的心脏事件:一项随机对照试验
Patrick W J C Serruys1, Pim de Feyter, Carlos Macaya
1Interventional Cardiology, Thoraxcenter, Bd 418, Academic Hospital, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. serruys@card.azr.nl
JAMA
|June 22, 2002
概括
在皮肤冠状动脉干预 (PCI) 后的患者中,弗卢瓦斯塔丁显著降低了主要不良心脏事件 (MACE). 这种他类药物治疗改善了长期的结果,降低了心脏病死亡,心脏病发作或重新干预的风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 穿皮冠状动脉干预 (PCI) 提供短期的症状缓解,但长期的重大心脏不良事件 (MACE) 风险仍然存在.
- 只有60%的PCI患者在5年后没有MACE,在10年后只有三分之一.
研究的目的:
- 为了研究弗卢瓦斯塔丁在降低PCI后患者的MACE的疗效.
- 评估弗卢瓦斯塔丁在成功的PCI后对长期心血管结果的影响.
主要方法:
- 一项随机,双盲,安慰剂对照试验,涉及77个欧洲,加拿大和巴西中心的1677名患者.
- 患者在PCI后的3-4年内接受80毫克/天的vastatin或安慰剂,MACE被定义为心脏死亡,非致命的心肌梗塞或重新干预.
主要成果:
- 弗卢瓦斯塔丁治疗显著增加了无MACE生存时间 (P=.01).
- 接受弗卢瓦斯塔丁治疗的患者在MACE风险下降了22% (RR 0.78,95% CI 0.64-0.95).
- 在糖尿病患者和多血管疾病患者中观察到显著的风险降低.
结论:
- 弗卢瓦斯塔丁有效降低PCI首次成功后平均胆固醇水平的患者发生重大心脏不良事件的风险.
- 无论基线胆固醇水平如何,弗鲁瓦斯塔丁的益处是一致的,在特定的患者亚组中尤其明显.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


